See more : SVB Financial Group (SIVBP) Income Statement Analysis – Financial Results
Complete financial analysis of Saniona AB (publ) (SANION.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Saniona AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Indus Finance Limited (INDUSFINL.BO) Income Statement Analysis – Financial Results
- Kid Castle Educational Corporation (KDCE) Income Statement Analysis – Financial Results
- FUJIFILM Holdings Corporation (FJI.F) Income Statement Analysis – Financial Results
- Gospell Digital Technology Co., Ltd. (002848.SZ) Income Statement Analysis – Financial Results
- PT Sumi Indo Kabel Tbk (IKBI.JK) Income Statement Analysis – Financial Results
Saniona AB (publ) (SANION.ST)
About Saniona AB (publ)
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.84M | 15.28M | 10.48M | 8.20M | 2.66M | 54.88M | 20.69M | 74.92M | 13.63M | 21.72M | 13.64M | 7.77M |
| Cost of Revenue | 5.06M | 4.48M | 4.63M | 3.25M | 3.52M | 4.09M | 3.26M | 1.48M | 2.05M | 1.73M | 676.02K | 1.06M |
| Gross Profit | 11.78M | 10.81M | 5.85M | 4.95M | -859.00K | 50.80M | 17.43M | 73.45M | 11.58M | 19.99M | 12.96M | 6.71M |
| Gross Profit Ratio | 69.96% | 70.72% | 55.81% | 60.33% | -32.32% | 92.55% | 84.23% | 98.03% | 84.96% | 92.04% | 95.04% | 86.41% |
| Research & Development | 0.00 | 96.40M | 155.70M | 0.00 | 0.00 | 0.00 | 26.90M | 29.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 239.27M | 97.11M | 74.98M | 80.15M | 51.39M | 51.10M | 23.93M | 15.02M | 5.11M | 5.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 1.86M | 239.27M | 97.11M | 74.98M | 80.15M | 51.39M | 51.10M | 23.93M | 15.02M | 5.11M | 5.17M |
| Other Expenses | 92.85M | 236.53M | 178.15M | 67.21M | 28.06M | 24.85M | 23.23M | 18.19M | 15.73M | 13.23M | 9.55M | 3.73M |
| Operating Expenses | 92.85M | 236.53M | 417.42M | 164.32M | 103.05M | 105.00M | 74.62M | 69.29M | 39.66M | 28.25M | 14.66M | 8.89M |
| Cost & Expenses | 97.91M | 241.00M | 422.05M | 167.57M | 106.56M | 109.09M | 77.88M | 70.76M | 41.71M | 29.98M | 15.34M | 9.95M |
| Interest Income | 2.24M | 593.00K | 247.00K | 312.00K | 674.00K | 0.00 | 0.00 | 9.00K | 0.00 | 0.00 | 1.00K | 0.00 |
| Interest Expense | 24.93M | 14.71M | 10.85M | 11.35M | 221.00K | 159.00K | 376.00K | 234.00K | 46.00K | 10.00K | 22.90K | 0.00 |
| Depreciation & Amortization | 9.65M | 7.82M | 8.67M | 4.80M | 2.20M | 632.00K | 561.00K | 384.00K | 763.00K | 760.00K | 449.00K | 2.18M |
| EBITDA | -82.01M | -196.00M | -398.86M | -64.64M | -68.71M | -53.68M | -55.71M | 4.54M | -28.50M | -6.98M | -1.22M | -2.18M |
| EBITDA Ratio | -486.97% | -1,424.98% | -3,848.59% | -1,976.14% | -3,050.34% | -86.55% | -267.44% | 7.38% | -208.72% | -32.09% | -9.09% | -28.12% |
| Operating Income | -81.07M | -225.72M | -411.57M | -159.38M | -103.91M | -54.21M | -57.19M | 4.16M | -28.08M | -8.26M | -1.70M | -2.18M |
| Operating Income Ratio | -481.38% | -1,476.93% | -3,927.94% | -1,944.07% | -3,909.18% | -98.76% | -276.39% | 5.55% | -205.98% | -38.02% | -12.46% | -28.12% |
| Total Other Income/Expenses | -23.22M | 7.19M | -6.81M | 78.16M | 17.16M | 5.91M | 914.00K | 757.00K | -1.18M | 519.00K | -13.00K | -13.85K |
| Income Before Tax | -104.28M | -251.97M | -418.38M | -81.22M | -83.50M | -48.29M | -56.28M | 4.91M | -29.26M | -7.74M | -1.71M | -2.20M |
| Income Before Tax Ratio | -619.24% | -1,648.67% | -3,992.94% | -990.68% | -3,141.50% | -87.99% | -271.97% | 6.56% | -214.66% | -35.63% | -12.55% | -28.30% |
| Income Tax Expense | -8.47M | -6.61M | -7.48M | -7.79M | -7.71M | -7.23M | -7.09M | 2.70M | -6.31M | -1.83M | -423.04K | -543.42K |
| Net Income | -95.81M | -245.36M | -410.90M | -73.43M | -75.79M | -41.06M | -49.19M | 2.22M | -22.95M | -5.91M | -1.29M | -1.65M |
| Net Income Ratio | -568.94% | -1,605.42% | -3,921.53% | -895.71% | -2,851.32% | -74.81% | -237.72% | 2.96% | -168.36% | -27.20% | -9.45% | -21.30% |
| EPS | -1.29 | -3.33 | -5.57 | -1.52 | -2.49 | -1.84 | -2.23 | 0.11 | -1.29 | -0.45 | -0.09 | -0.12 |
| EPS Diluted | -1.29 | -3.33 | -5.57 | -1.52 | -2.49 | -1.84 | -2.23 | 0.11 | -1.26 | -0.43 | -0.09 | -0.12 |
| Weighted Avg Shares Out | 74.54M | 73.73M | 73.73M | 48.45M | 30.40M | 22.29M | 22.02M | 20.84M | 17.78M | 13.13M | 14.27M | 14.27M |
| Weighted Avg Shares Out (Dil) | 74.54M | 73.73M | 73.73M | 48.45M | 30.40M | 22.31M | 22.06M | 21.43M | 18.28M | 13.60M | 14.27M | 14.27M |
Source: https://incomestatements.info
Category: Stock Reports